Slide 1: Q4 2022 Quarterly Business Update
Q4 2022 Quarterly Business Update Telix Pharmaceuticals (ASX:TLX) 18 January 2023
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied,
Slide 3: Today's presenters
Today’s presenters Kyahn Williamson Dr Christian Behrenbruch Darren Smith SVP INVESTOR GROUP CEO AND GROUP CHIEF R E L AT I O N S & MANAGING DIRECTOR FINANCIAL OFFICER C O R P O R AT E C O M M U N I C AT I O N
Slide 4: Q4 2022 Highlights
Q4 2022 Highlights QTelix ae
Slide 5: Building on a transformative year
Building on a transformative year Major milestones delivered, value creating catalysts ahead Key milestones in Q4 20221 Revenue from U.S. Illuccix® sales 2023 catalysts Q2 to Q4 2022 • Achieved positive cash flow • Illuccix® - continued from operating activities, $1.6M Q4 2022 revenue growth and glo
Slide 6: Q4 2022 key financial metrics
Q4 2022 key financial metrics Telix reports first positive cash flow quarter Total revenue U.S. sales revenue Receipts from customers Cash balance $78.2M $76.8M $72.2M $116.3M Up 41 percent from Up 43 percent from Up 62 percent from As of 31 Dec 2022 $55.3M in Q3 2022 $53.7M in Q3 2022 $44.5M in Q3
Slide 7: Illuccix revenue continues to grow
Illuccix® revenue continues to grow Q4 performance evidence of strong growth trajectory • Revenue from U.S. sales of Illuccix up 43% to $76.8M (US$50.5M) on the prior quarter Revenue from U.S. Sales of Illuccix ($M) 90.0 • Reimbursement improving across MACs1 as Telix 80.0 76.8 specific code is leve
Slide 8: Financial Commentary
Financial Commentary QTelix —— ae
Slide 9: Q4 records positive operating cash flow of $1.6M
Q4 records positive operating cash flow of $1.6M First quarter of net cash inflow from operating activities • Quarterly cash flow improved $6.9M over prior quarter with a positive $1.6M inflow • Customer receipts of $72.2M, improved 62% over prior quarter, reflecting sales growth and improved collec
Slide 10: Sales performance and controlling operating expenditure
Sales performance and controlling operating expenditure Funding focused investment in priority programs Revenue ($M) and gross margin percentage • Gross margin improvement of 2% from Q3 to Q4 63% 90.0 reflects further efficiency gains in manufacturing costs 80.0 61% 70.0 78.2 • Operating expenditure
Slide 11: Four major focus areas in 2023
Four major focus areas in 2023 Value creating catalysts across the imaging and therapeutic pipeline ProstACT New Drug Illuccix® - GLOBAL patient Biologics License Application (NDA) continued revenue recruitment and Application (BLA) for brain cancer growth and global ProstACT submission for imaging
Slide 12: PSMA competitive landscape
PSMA competitive landscape TLX591 Telix approach is highly differentiated Liver (preferred clearance organ) ANTIBODY (TLX591) SMALL MOLECULES Functionally specific for tumour- expressed PSMA, does not “hit” most Taken up by endogenous PSMA Fecal endogenous PSMA excretion Small molecule Off-target ef
Slide 13: TLX591: ProstACT GLOBAL study overview
TLX591: ProstACT GLOBAL study overview U.S. and EU patient enrolment commencing in 2023 RUN-IN PHASE III Summary Stratification Group A • Total patients: ~392 • Prior NAAD1 Group A 76 mCi 177Lu-DOTA- 76 mCi 177Lu-DOTA- • “Run-in” to accommodate new scale-up therapy in csPRC2 • Disease burden rosopat
Slide 14: TLX101-CDx: value proposition for glioma imaging
TLX101-CDx: value proposition for glioma imaging Potential to lead with first commercial FET-PET solution for U.S. market Reduce and/or replace Provide key information surgical biopsies at initial • FET-PET has the potential to provide a rapid and conclusive diagnosis 1 diagnosis to enable optimal t
Slide 15: TLX250-CDx: imaging agent with high commercial potential
TLX250-CDx: imaging agent with high commercial potential Strong results support potential for TLX250-CDx to change standard of care Top-line data reported in November 20221 Planning for FDA regulatory approval in 2024 • 93% positive predictive value (PPV) • Phase III data demonstrates TLX250-CDx pro
Slide 16: TLX250-CDx: U.S. market opportunity
TLX250-CDx: U.S. market opportunity Identification and characterisation of ccRCC FUTURE New incidental Renal cancer Active surveillance for Previously treated renal mass diagnosis known renal mass ccRCC high risk • Estimated 73,994 incidental • 79,000 patients will be • Prevalence unknown • 599,000
Slide 17: Upcoming catalysts
Upcoming catalysts New Drug ProstACT Illuccix® - Biologics License GLOBAL patient Four key continued Application (NDA) Application (BLA) for brain cancer recruitment and catalysts revenue growth submission for data readout and global imaging TLX250-CDx (TLX101-CDx) ProstACT rollout SELECT EXPECTED M
Slide 18: Contact details
Contact details: Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com 18